alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
United States of America

OCCUPATIONAL SAFETY AND HEALTH REVIEW COMMISSION

 1120 20th Street, N.W., Ninth Floor

 Washington, DC 20036-3457

SECRETARY OF LABOR,

Complainant,

v. OSHRC Docket No. 19-0622

ANTHONY MARANO CO.,

Respondent.

BRIEFING NOTICE

The parties are requested to brief the following issues:

(1) Did the judge err in affirming Citation 1, Item 1, as a sanction for Respondent’s failure to 

comply with an order requiring the production of documents for in camera review?

(2) With respect to Citation 1, Item 2, did the judge err in finding the cited standard, 29 

C.F.R. § 1910.147(d) (lockout/tagout procedures), applies? Specifically, the parties 

are requested to brief the following:

a. Did the judge err in finding that the cited work activities constitute “servicing

and/or maintenance” outside of normal production? See 29 C.F.R. 

§ 1910.147(a)(2)(i), (ii)?

b. Did the judge err in finding the minor servicing exception does not apply? 

See 29 C.F.R. § 1910.147(a)(2)(ii)(B) (note)?

(3) Did the judge err in affirming Citation 2, Item 1?

All briefs are to be filed in accordance with Commission Rule 93.1 The first brief is to be 

filed within 40 days of this notice. A party not intending to file a brief shall notify the Commission 

in accordance with Commission Rule 93. The time for filing any responsive briefs (or letters filed 

in lieu of briefs) shall commence on the date of service.

BY DIRECTION OF THE COMMISSION

Dated: February 16, 2022 /s/

John X. Cerveny

Executive Secretary

1 The Commission requests that all briefs include an alphabetical table of authorities with 

references to the pages on which they are cited, and that an asterisk be placed in the left-hand 

margin of the table to indicate those authorities on which the brief principally relies. The 

Commission also requests that copies of cited authority, other than statutes, regulations, case law, 

law journal articles, and legal treatises, be provided to the Commission and to the opposing party. 

Parties should be cautioned that these materials will be considered only if appropriate.
In the United States Court of Federal Claims 

OFFICE OF SPECIAL MASTERS

No. 20-587V

UNPUBLISHED

HELEN MORTON,

 Petitioner,

v.

SECRETARY OF HEALTH AND 

HUMAN SERVICES,

 Respondent.

Chief Special Master Corcoran 

Filed: October 12, 2021

Special Processing Unit (SPU); 

Ruling on Entitlement; Concession;

Table Injury; Influenza (Flu) Vaccine;

Shoulder Injury Related to Vaccine 

Administration (SIRVA)

Leah VaSahnja Durant, Law Offices of Leah V. Durant, PLLC, Washington, DC, for 

Petitioner.

Emilie Williams, U.S. Department of Justice, Washington, DC, for Respondent.

RULING ON ENTITLEMENT1

On May 12, 2020, Helen Morton filed a petition for compensation under the 

National Vaccine Injury Compensation Program, 42 U.S.C. §300aa-10, et seq.2 (the 

“Vaccine Act”). Petitioner alleges that she suffered from a left shoulder injury related to 

vaccine administration (“SIRVA”) caused by an influenza vaccine administered on 

December 14, 2018. Petition at 1. Petitioner further alleges that the vaccine was 

administered within the United States, that she has suffered the residual effects of her 

injury fore more than six months, and that there has been no award or civil settlement for 

her vaccine-related injury. Petition at 4. The case was assigned to the Special Processing 

Unit of the Office of Special Masters.

1 Because this unpublished Ruling contains a reasoned explanation for the action in this case, I am required 

to post it on the United States Court of Federal Claims' website in accordance with the E-Government Act 

of 2002. 44 U.S.C. § 3501 note (2012) (Federal Management and Promotion of Electronic Government 

Services). This means the Ruling will be available to anyone with access to the internet. In accordance 

with Vaccine Rule 18(b), Petitioner has 14 days to identify and move to redact medical or other information, 

the disclosure of which would constitute an unwarranted invasion of privacy. If, upon review, I agree that 

the identified material fits within this definition, I will redact such material from public access. 

2 National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755. Hereinafter, for ease 

of citation, all section references to the Vaccine Act will be to the pertinent subparagraph of 42 U.S.C. § 

300aa (2012).
2

On October 6, 2021, Respondent filed his Rule 4(c) report in which he concedes

that Petitioner is entitled to compensation in this case. Respondent’s Rule 4(c) Report at 

1. Specifically, Respondent has concluded that Petitioner meets the Table criteria for a 

SIRVA. Id. at 6. Respondent further agrees that Petitioner has satisfied the statutory 

requirements for compensation. Id.

In view of Respondent’s position and the evidence of record, I find that 

Petitioner is entitled to compensation.

IT IS SO ORDERED.

s/Brian H. Corcoran

Brian H. Corcoran

Chief Special Master
<TABLE> <S> <C>

<ARTICLE> 9
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               MAR-31-1999
<CASH>                                      4,404,838
<INT-BEARING-DEPOSITS>                      3,505,775
<FED-FUNDS-SOLD>                              630,000
<TRADING-ASSETS>                                    0
<INVESTMENTS-HELD-FOR-SALE>                 3,884,688
<INVESTMENTS-CARRYING>                      5,548,818
<INVESTMENTS-MARKET>                        5,548,818
<LOANS>                                    76,544,899
<ALLOWANCE>                                   388,863
<TOTAL-ASSETS>                            101,599,353
<DEPOSITS>                                 86,954,578
<SHORT-TERM>                                2,500,000
<LIABILITIES-OTHER>                           495,516
<LONG-TERM>                                         0
<COMMON>                                        6,077
<PREFERRED-MANDATORY>                               0
<PREFERRED>                                         0
<OTHER-SE>                                 10,253,638
<TOTAL-LIABILITIES-AND-EQUITY>            101,599,353
<INTEREST-LOAN>                             1,633,336
<INTEREST-INVEST>                             145,789
<INTEREST-OTHER>                               83,863
<INTEREST-TOTAL>                            1,862,988
<INTEREST-DEPOSIT>                            942,321
<INTEREST-EXPENSE>                            972,944
<INTEREST-INCOME-NET>                         890,044
<LOAN-LOSSES>                                  22,500
<SECURITIES-GAINS>                                  0
<EXPENSE-OTHER>                               169,027
<INCOME-PRETAX>                               287,629
<INCOME-PRE-EXTRAORDINARY>                    287,629
<EXTRAORDINARY>                                     0
<CHANGES>                                           0
<NET-INCOME>                                  175,439 
<EPS-PRIMARY>                                    0.30 
<EPS-DILUTED>                                    0.30 
<YIELD-ACTUAL>                                   3.77
<LOANS-NON>                                   437,915
<LOANS-PAST>                                  102,347
<LOANS-TROUBLED>                                    0
<LOANS-PROBLEM>                                     0
<ALLOWANCE-OPEN>                              402,309
<CHARGE-OFFS>                                  41,230 
<RECOVERIES>                                    5,284
<ALLOWANCE-CLOSE>                             388,862
<ALLOWANCE-DOMESTIC>                          388,862
<ALLOWANCE-FOREIGN>                                 0
<ALLOWANCE-UNALLOCATED>                             0
        

</TABLE>
# Official Journal C 113/25 M

| | ISSN 1977-091X |
| --- | --- |
| Official Journal
  of the European Union | C 113 |
| | |
| English edition | Information and Notices | Volume 6225 March 2019 |

ISSN 1977-091X

Official Journal

of the European Union

C 113

English edition

Information and Notices

Volume 6225 March 2019

---

| Contents | page |
| --- | --- |
| | II   Information |
| | INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2019/C 113/01 | Common catalogue of varieties of agricultural plant species — third supplement to the 37th complete edition | 1 |

Contents

page

II   Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2019/C 113/01

Common catalogue of varieties of agricultural plant species — third supplement to the 37th complete edition

1

---

| EN | |
| --- | --- |

EN
II

106TH CONGRESS

1ST SESSION S. 833

To make technical corrections to the Health Professions Education Partnerships Act of 1998 with respect to the Health Education Assistance

Loan Program.

IN THE SENATE OF THE UNITED STATES

APRIL 20, 1999

Mr. FRIST (for himself, Mr. KENNEDY, Mr. JEFFORDS, and Mr. BINGAMAN)

introduced the following bill; which was read twice and referred to the

Committee on Health, Education, Labor, and Pensions

A BILL

To make technical corrections to the Health Professions Education Partnerships Act of 1998 with respect to the

Health Education Assistance Loan Program.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. AMENDMENTS WITH RESPECT TO THE HEALTH

4 EDUCATION ASSISTANCE LOAN PROGRAM.

5 (a) IN GENERAL.—Section 707(a) of the Public

6 Health Service Act (42 U.S.C. 292f(a)) is amended—

7 (1) in paragraph (1), by striking ‘‘determined,’’

8 and all that follows through the period and inserting

9 ‘‘determined.’’;
2

•S 833 IS

1 (2) by striking paragraph (2); and

2 (3) by striking ‘‘(a) CONDITIONS’’ and all that

3 follows through ‘‘(1) IN GENERAL.—Upon’’ and in4 serting the following:

5 ‘‘(a) CONDITIONS FOR PAYMENT TO BENEFICIARY.—

6 Upon’’.

7 (b) DEFINITION.—Section 707(e) of the Public

8 Health Service Act (42 U.S.C. 292f(e)) is amended by

9 striking paragraph (4).

10 (c) EFFECTIVE DATE.—The amendments made by

11 subsections (a) and (b) shall apply with respect to loans

12 submitted to the Secretary of Health and Human Services

13 for payment on or after May 1, 1999.

Æ
Exhibit 31.1CERTIFICATIONSI, Jay S. Wintrob, Chief Executive Officer of First SunAmerica Life Insurance Company, certifythat:1. I have reviewed this Quarterly Report on Form 10-Q of First SunAmerica Life InsuranceCompany; 2. Based on my knowledge, this report does not contain any untrue statement of a material factor omit to state a material fact necessary to make the statements made, in light of thecircumstances under which such statements were made, not misleading with respect to the periodcovered by this report; 3. Based on my knowledge, the financial statements, and other financial information included inthis report, fairly present in all material respects the financial condition, results ofoperations and cash flows of the registrant as of, and for, the periods presented in thisreport; 4. The registrant’s other certifying officer and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and15d-15(e)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controlsand procedures to be designed under our supervision, to ensure that material informationrelating to the registrant, including its consolidated subsidiaries, is made known to us byothers within those entities, particularly during the period in which this report is beingprepared;  (b) [Omitted pursuant to SEC Release No. 33-8238];  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures andpresented in this report our conclusions about the effectiveness of the disclosure controlsand procedures, as of the end of the period covered by this report based on suchevaluation; and  (d) Disclosed in this report any change in the registrant’s internal control over financialreporting that occurred during the registrant’s most recent fiscal quarter (theregistrant’s fourth fiscal quarter in the case of an annual report) that has materiallyaffected, or is reasonably likely to materially affect, the registrant’s internal controlover financial reporting; and5. The registrant’s other certifying officer and I have disclosed, based on our most recentevaluation of internal control over financial reporting, to the registrant’s auditors and theaudit committee of the registrant’s board of directors (or persons performing the equivalentfunctions): (a) All significant deficiencies and material weaknesses in the design or operation ofinternal control over financial reporting which are reasonably likely to adversely affectthe registrant’s ability to record, process, summarize and report financial information;and  (b) Any fraud, whether or not material, that involves management or other employees whohave a significant role in the registrant’s internal control over financial reporting.Date: August 12, 2005   /s/ JAY S. WINTROB     Jay S. Wintrob  Chief Executive Officer
Occupational Safety and Health Review Commission

Commission Monthly Case Activity for December 2020

1. Cases Pending Beginning of Month 25

2. Cases Added to Docket 1 

Henkels & McCoy, Inc.

No. 18-1864

Directed for Review on December 7, 2020

 

3. Cases Subtracted from Docket -3 

Walmart, Inc.

No. 17-0949

Decision issued on December 31, 2020

Mansfield Industrial, Inc.

No. 17-1214

Decision issued on December 31, 2020

Burlington Capital PM Group, Inc. d/b/a Post Woods Apartment Homes

No. 20-0528

Remand Order issued on December 31, 2020

4. Total Cases Pending End of Month 23
```

[Federal Register Volume 79, Number 133 (Friday, July 11, 2014)]
[Rules and Regulations]
[Page 39972]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-16303]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF STATE

22 CFR Part 34

[Public Notice: 8791]
RIN 1400-AD60

Debt Collection

AGENCY: Department of State.

ACTION: Final rule; correction.

-----------------------------------------------------------------------

SUMMARY: The Department of State (hereinafter, ``State'' or ``the 
Department'') is publishing a correction to a final rule that amended 
State's debt collection regulations.

DATES: This rule will become effective on July 11, 2014.

FOR FURTHER INFORMATION CONTACT: Alice Kottmyer, Office of the Legal 
Adviser, United States Department of State; phone: (202) 647-2199; 
email: KottmyerAM@state.gov.

SUPPLEMENTARY INFORMATION: As part of the June 20, 2014 Federal 
Register (79 FR 35282) final rule amendatory text, the Department 
erroneously removed ``22 CFR 34.7(a)(7)'', which does not exist. The 
Department's intent, however, was to remove 22 CFR 34.10(a)(7), for the 
reasons explained in the prior document. This document corrects that 
error.

List of Subjects in 22 CFR Part 34

    Administrative practice and procedure, Claims, Debts, Garnishment 
of wages, Government employee, Hearing and appeal procedures, Pay 
administration, Salaries, Wages.

    For the reasons stated in the preamble, 22 CFR part 34 is amended 
as follows:

PART 34--DEBT COLLECTION

0
1. The authority citation for part 34 continues to read as follows:

    Authority:  31 U.S.C. 3701-3719; 5 U.S.C. 5514; 31 CFR part 285; 
31 CFR parts 900-904; 5 CFR part 550, subpart K.

Sec.  34.10  [Amended]

0
2. Remove paragraph (a)(7) from Sec.  34.10.

    Dated: July 3, 2014.
Janet M. Freer,
Director, Office of Directives Management, Department of State.
[FR Doc. 2014-16303 Filed 7-10-14; 8:45 am]
BILLING CODE 4710-37-P
```
<TABLE> <S> <C>

<PAGE>
 
<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          SEP-30-1998
<PERIOD-START>                             OCT-01-1997
<PERIOD-END>                               MAR-29-1998
<CASH>                                          38,343
<SECURITIES>                                     6,185
<RECEIVABLES>                                   40,444
<ALLOWANCES>                                         0
<INVENTORY>                                     38,251
<CURRENT-ASSETS>                               149,986
<PP&E>                                          13,691
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 167,711
<CURRENT-LIABILITIES>                           41,282
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           195
<OTHER-SE>                                     126,095
<TOTAL-LIABILITY-AND-EQUITY>                   167,711
<SALES>                                        112,257
<TOTAL-REVENUES>                               112,257
<CGS>                                           63,559
<TOTAL-COSTS>                                   63,559
<OTHER-EXPENSES>                                52,253<F1>
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   9
<INCOME-PRETAX>                                (2,983)
<INCOME-TAX>                                     2,209
<INCOME-CONTINUING>                            (5,192)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (5,192)
<EPS-PRIMARY>                                     0.27
<EPS-DILUTED>                                     0.27
<FN>
<F1>Other expenses include $8,417 acquired in-process research and development
costs and $6,813 of merger and other non-recurring costs.
</FN>
        

</TABLE>
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
                             FINANCIAL DATA SCHEDULE

This schedule  contains  summary  financial  information  extracted from Balance
Sheet,  Statement  of  Operations,  Statement  of Cash  Flows and Notes  thereto
incorporated  in Part 1, Item 1, of this Form  10-QSB  and is  qualified  in its
entirety by reference to such financial statements.

</LEGEND> 
       
<S>                                                           <C>  
<PERIOD-TYPE>                                                 9-MOS
<FISCAL-YEAR-END>                                              mar-31-1997
<PERIOD-END>                                                   dec-31-1997
<CASH>                                                         2,827,735
<SECURITIES>                                                   0  
<RECEIVABLES>                                                  317,121
<ALLOWANCES>                                                   0
<INVENTORY>                                                    6,612,013
<CURRENT-ASSETS>                                               9,920,293
<PP&E>                                                         6,157,635
<DEPRECIATION>                                                 (3,268,948)
<TOTAL-ASSETS>                                                 12,987,642
<CURRENT-LIABILITIES>                                          9,043,055
<BONDS>                                                        0
<PREFERRED-MANDATORY>                                          0
<PREFERRED>                                                    5,966,549
<COMMON>                                                       0
<OTHER-SE>                                                     (2,202,960)
<TOTAL-LIABILITY-AND-EQUITY>                                   12,987,642
<SALES>                                                        17,768,033
<TOTAL-REVENUES>                                               17,768,033  
<CGS>                                                          10,740,074
<TOTAL-COSTS>                                                  0
<OTHER-EXPENSES>                                               7,213,223
<LOSS-PROVISION>                                               0
<INTEREST-EXPENSE>                                             683,653
<INCOME-PRETAX>                                                (868,917)
<INCOME-TAX>                                                   0  
<INCOME-CONTINUING>                                            0
<DISCONTINUED>                                                 0
<EXTRAORDINARY>                                                0
<CHANGES>                                                      0 
<NET-INCOME>                                                   (868,917)
<EPS-PRIMARY>                                                  (0.21)
<EPS-DILUTED>                                                  (0.21)


        
                           

</TABLE>
f8k102010ex10lxxxi_naturaln.htm


 


Exhibit 10.81








 


NaturalNano, Inc.


15 Schoen Place


Pittsford, NY 14534


 


October 20, 2010


 


Longview Special Finance Inc. 


C/o LH Financial 150


Central Park South


2nd Floor


New York, NY 10019


 


Ladies and Gentlemen:


 


This letter shall serve as the agreement and promise of NaturalNano, Inc. (the "Company") to pay to the order of Longview Special Finance Inc. ("Longview"), the sum of $3077 plus interest at 8 % per annum. The Company acknowledges that Longview has advanced $3077 in funds at the Company's request, and the Company's obligations hereunder shall be secured by all other collateral that secures the various senior secured promissory notes that the Company has previously issued to Longview. In the event the Company fails to repay Longview in accordance with the terms of this letter, Longview should be entitled to exercise all rights granted to it as a secured creditor pursuant to the Security Agreements (as defined in the 8% Senior Secured Promissory Note issued to Longview by the Company on or about November 5, 2008).


 


All payments under or pursuant to this Note shall be made in United States Dollars, in immediately available funds, to Longview at the address set forth above or at such other place as Longview may designate from time to time in writing to the Company or by wire transfer of funds to Longview's account, as requested by Longview. The outstanding principal balance of this Note, together with all accrued and unpaid interest, shall be due and payable in full on January 15, 2011.


 


 


 


Very truly yours, 


 


Natural Nano, Inc.


 


 


By:  /s/ James Wemett                       


Name: James Wemett


Title: CEO